Clinical Trials · NCT03947762

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.

Name: Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedN/ALanreotide

Phase: N/A
Recruitment status: Terminated
Sponsor: Ipsen
Enrollment: 54
Start date: Jul 2019
Locations: 46 sites, Portugal, Spain
Primary endpoint: Progression-free survival (PFS) rate at 24 months

View Lanreotide compound reference